$10 billion for an immunotherapy that can be applied to a WIDE range of cancers is a bit absurd and low, don't you think?
I agree that the other "pie in the sky" assessments are wild, but only $10 billion? We've seen companies offer more than twice that amount on indications regarding a niche medical issue on PH II data ONLY.
They've expressed a desire to expand the executive team. They started the economic model analysis months ago for NICE. They have 2 Roswell trials that are ongoing that they have inlicensed tech. Just revised the pediatric trial. Signed a partner for direct trials (which I believe are on hold until the draft guidance is final from the MHRA). They're securing manufacturing in the US for some of the Roswell technology. None of this screams buyout.
Market Data 
Markets 
Hi Sir, Dr.Carlo Rago's prediction $30+ base on te platform of Dcvax . Michael Bigger asked him to make a write paper to support nwbo 3 years ago.
